Three Orelabrutinib Studies Selected for Oral Sessions at Japanese Hematology Meeting
InnoCare Pharma said three studies of orelabrutinib were selected for oral presentation at the 88th Annual Meeting of the Japanese Society of Hematology.
InnoCare Pharma said three studies of orelabrutinib were selected for oral presentation at the 88th Annual Meeting of the Japanese Society of Hematology.